SEATTLE, WA (July 20, 2015): Quorum Review IRB, the premier central IRB, is introducing a comprehensive program that supports the unique needs of Phase I Healthy clinical trials. Quorum knows that Phase I units require immediate service and quick turnaround times. Quorum’s new program delivers.
With Quorum Review’s new Phase 1 Healthy Program, a study can be ready to enroll participants within a few days of submitting their materials. For changes mid-study, review and delivery of approval documents is even faster. Quorum’s new program also provides unprecedented alternatives in the review of recruitment materials. Quorum can conditionally approve recruitment materials before the protocol review is finalized, so you can more proactively plan for their deployment. If your group leverages generic recruitment templates and generic screening consent forms, Quorum’s new program makes using those materials easier than ever.
Quorum’s customers that have had the opportunity to preview the new Phase 1 Healthy Program proclaim it to be the “most intuitive service offering that exists for Phase 1 Healthy research.” “We know Phase I,” says Quorum’s CEO, Cami Gearhart. “We have Phase I researchers on our IRB panels and staff dedicated to supporting Phase I services. We are proud to offer our clients nimble turnaround times as well as the reliability of a large, accredited IRB.”
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.